Alternative complement pathway activation during invasive coronary procedures in acute myocardial infarction and stable angina pectoris.
暂无分享,去创建一个
I. Préda | R. Kiss | Z. Prohászka | K. Vargová | D. Csuka | L. Varga | Z. Horvath | Andrea Kovács | Sarolta Leé | Emese Tóth Zsámboki | Z. Horváth
[1] T. Funahashi,et al. High serum C1q-binding adiponectin levels in male patients with acute coronary syndrome , 2014, Cardiovascular Diabetology.
[2] M. Osthoff,et al. Impact of Mannose-Binding Lectin Deficiency on Radiocontrast-Induced Renal Dysfunction , 2013, BioMed research international.
[3] I. Préda,et al. Elevated C1rC1sC1inh levels independently predict atherosclerotic coronary heart disease. , 2013, Molecular immunology.
[4] S. Pedersen,et al. Soluble form of membrane attack complex independently predicts mortality and cardiovascular events in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. , 2012, American heart journal.
[5] Fred S Apple,et al. Third universal definition of myocardial infarction , 2012 .
[6] Erdmann Seeliger,et al. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. , 2012, European heart journal.
[7] P. Armstrong,et al. Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. , 2012, American heart journal.
[8] S. Thiel,et al. Complement Activation and Prognosis in Patients With Type 2 Diabetes and Myocardial Infarction , 2012, Diabetes Care.
[9] Raimund Erbel,et al. [2011 ESC guidelines on the diagnosis and treatment of peripheral artery diseases]. , 2012, Revue medicale de Liege.
[10] C. Held,et al. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. , 2011, JAMA.
[11] Volkmar Falk,et al. Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .
[12] J. Hartikainen,et al. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries , 2009, European heart journal.
[13] M. Alpert,et al. Effect of radiographic contrast media on markers of complement activation and apoptosis in patients with chronic coronary artery disease undergoing coronary angiography. , 2009, The Journal of invasive cardiology.
[14] O. Wagner,et al. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction , 2009, Thrombosis and Haemostasis.
[15] Sonia Youhanna,et al. Comparison of the systemic levels of inflammatory markers after percutaneous coronary intervention with bare metal versus sirolimus-eluting stents. , 2009, Journal of interventional cardiology.
[16] G. Biondi-Zoccai,et al. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. , 2008, The Journal of thoracic and cardiovascular surgery.
[17] L. Entz,et al. Early complement activation follows eversion carotid endarterectomy and correlates with the time of clamping of the carotid artery. , 2008, Molecular immunology.
[18] W. Gray,et al. Endovascular therapies for peripheral arterial disease: an evidence-based review. , 2007, Circulation.
[19] O. Wiklund,et al. Dissociation of the Inflammatory Reaction following PCI for Acute Myocardial Infarction. , 2007, The Journal of invasive cardiology.
[20] S. Meri,et al. Function and regulation of the complement system in cardiovascular diseases. , 2007, Frontiers in bioscience : a journal and virtual library.
[21] T. Woodruff,et al. Complement mediators in ischemia-reperfusion injury. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[22] C. Becker,et al. Pathophysiology of contrast-induced nephropathy. , 2006, The American journal of cardiology.
[23] V. Hasselblad,et al. Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview. , 2006, American heart journal.
[24] T. Omland,et al. Inflammatory response and re-stenosis after percutaneous coronary intervention in heart transplant recipients and patients with native atherosclerosis. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[25] N. Toprak,et al. Complement activation in acute coronary syndromes , 2005, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[26] C. Stefanadis,et al. Inflammation and restenosis after percutaneous coronary interventions. , 2004, European heart journal.
[27] P. Kovanen,et al. Role of complement activation in atherosclerosis , 2003, Current opinion in lipidology.
[28] H. Dauerman,et al. Increase in Interleukin-6 in the First Hour after Coronary Stenting: An Early Marker of the Inflammatory Response , 2003, Journal of Thrombosis and Thrombolysis.
[29] A. Keren,et al. Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease. , 2003, American heart journal.
[30] M. Walport,et al. Complement. Second of two parts. , 2001, The New England journal of medicine.
[31] M. Walport. Complement. First of two parts. , 2001, The New England journal of medicine.
[32] S. Meri,et al. Complement activation after oxidative stress: role of the lectin complement pathway. , 2000, The American journal of pathology.
[33] G. Stone,et al. Long-term clinical events following creatine kinase--myocardial band isoenzyme elevation after successful coronary stenting. , 2000, Journal of the American College of Cardiology.
[34] Wiklund Ra,et al. First of two parts , 1997 .
[35] J. Kowalski,et al. Complement activates neutrophils during PTCA procedure in patients with unstable angina pectoris. , 1997, International journal of cardiology.
[36] E. Topol,et al. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. , 1996, Circulation.
[37] E. Topol,et al. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. , 1996, American heart journal.
[38] D. Baim,et al. Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. , 1994, The American journal of cardiology.
[39] Mosteller Rd. Simplified Calculation of Body-Surface Area , 1987 .
[40] W. Hollander,et al. Soluble proteins in the human atheroschlerotic plaque , 1979 .
[41] P. Garred,et al. The Lectin Pathway of Complement and Biocompatibility. , 2015, Advances in experimental medicine and biology.
[42] D. McManus,et al. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. , 2011, The American journal of medicine.
[43] T. Ueland,et al. Inflammatory response to percutaneous coronary intervention in stable coronary artery disease , 2010, Journal of Thrombosis and Thrombolysis.
[44] G. Maurer,et al. Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a. , 2010, Atherosclerosis.
[45] M. Saletti,et al. Changes of some immune functions after percutaneous transluminal coronary angioplasty (PTCA). , 1995, International journal of clinical pharmacology research.
[46] S. Rendig,et al. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. , 1995, The American journal of physiology.
[47] I. Toda,et al. The complement system in ischemic heart disease. , 1990, Circulation.